What does it take to commercialize academic innovation?

Join us for an interactive discussion of translational research in academia and biotech, with networking and refreshments. RSVP here.

Featuring Ivana Magovcevic-Liebisch, JD, PhD, Senior Vice President and Head of Global Business Development for Teva Pharmaceuticals.

Dr. Magovcevic-Liebisch has led and executed business development transactions, including licensing and acquisition of companies, businesses, commercial products, drug candidates and/or technologies, to support operational strategies and objectives of Teva’s Global Specialty R&D and Commercial Franchises to drive growth and value for the company.

She was previously Executive Vice President and Chief Operating Officer at Dyax Corp. where she established the commercial infrastructure of the company’s first FDA-approved drug, Kalbitor® for treatment of hereditary angioedema attacks, a very rare and potentially life-threatening genetic condition. Prior to Dyax, she was Director of Intellectual Property and Patent Counsel for Transkaryotic Therapies, Inc.

Dr. Magovcevic-Liebisch currently serves as a member of the Board of Directors of AGTC, a biotech company developing cures for rare eye diseases through gene therapy, a Trustee of the Wentworth Institute of Technology, and an overseer of the Boston Ballet.

Dr. Magovcevic holds a Ph.D. in Genetics from Harvard University and received her J.D. in High Technology law from Suffolk University Law School. In 2008, she was the winner of the Woman Entrepreneurs in Science and Technology Leadership Award.

Sign up to receive OTD newsletters here: http://otd.harvard.edu/mailing-signup/